Learn how you can stall the development of full-blown Multiple Myeloma with evidence-based nutritional and supplementation therapies.
Click the orange button to the right to learn more.
Monoclonal Gammopathies of Clinical Significance (MGCS)- what used to be simply MGUS or SMM is now more than that.
“Monoclonal gammopathy of clinical significance (MGCS) refers to a recently coined term describing a complex and heterogeneous group of nonmalignant monoclonal gammopathies. These patients are characterized by the presence of a commonly small clone and the occurrence of symptoms that may be associated with the clone or with the monoclonal protein through diverse mechanisms.
This is an evolving, challenging, and rapidly changing field.
Patients are classified according to the key organ or system involved, with
being the most frequently affected. However, multiorgan involvement may be the most relevant clinical feature at the presentation or during the course…”
SBP, MGUS and SMM are pre-myeloma stages for multiple myeloma.
Monoclonal Gammopathy of Undetermined Significance or MGUS is an asymptomatic blood disorder in which a paraprotein is found in the blood during standard laboratory blood tests” according to Wikipedia.
The good news is that MGUS is a blood disorder and is relatively harmless. The bad news is that MGUS as a blood disorder can lead to a diagnosis of full blown multiple myeloma- an incurable blood cancer.
According to a study conducted by the Mayo Clinic, approximately 3% of people over 50 have MGUS. The percentage of African-Americans who have this blood disorder is approximately 5%. The same Mayo Clinic study estimated that the risk of MGUS patients progressing to Multiple Myeloma is 1.0-1.5 annually. This risk might not sound like much but that risk increases slightly each year for the rest of your life.
MGUS at a glance-
MGUS can have many symptoms and can lead to many different health issues (see the list below).
I have listed many of the associated diseases simply to show you how complicated monoclonal proteins can be. Diagnosing and identifying your specific issues may be a challenge.
Have you been diagnosed with MGUS? Do you have symptoms despite your oncologist telling you that MGUS is asymptomatic?
You may have a “blood disorder” but drilling down to identify a specific disease may be a real challenge for your and your physician.
Scroll down the page, post a question or comment and I will reply to you ASAP.
Hang in there,
The spectrum of various disorders associated with MGUS, in the absence of MM, Waldenström macroglobulinemia, or other lymphoproliferative disorders, describes a new entity of MGCS, the management of which remains a subject of further research and is yet to be determined.
Apart from a few diseases, in which specific etiological or pathogenic therapeutic options are known (e.g., anakinra for Schnitzler syndrome or C1 inhibitor concentrate for acquired C1 inhibitor deficiency), treatment of MGCS involves myeloma-targeting agents or immunosuppressive and immunomodulatory medications, depending on the type of the disorder associated with M protein.